Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Brigham and Women's Hospital · Harvard University · +13 more institutions
Abstract
The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.
We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke.
Citation impact
- FWCI
- 217.95
- Percentile
- 100%
- References
- 38
Authors
18- BMBenjamin M. SciricaCorresponding
Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group
- DLDeepak L. Bhatt
Brigham and Women's Hospital, Harvard University, VA Boston Healthcare System, Thrombolysis in Myocardial Infarction Study Group
- EBEugene Braunwald
Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group
- PGPhilippe Gabríel Steg
Inserm, Université Paris Cité, Southwestern Medical Center, Hôpital Bichat-Claude-Bernard, The University of Texas Southwestern Medical Center
- JAJaime A. Davidson
The University of Texas Southwestern Medical Center
Topics & keywords
- Saxagliptin
- Medicine
- Hazard ratio
- Myocardial infarction
- Internal medicine
- Heart failure
- Placebo
- Stroke (engine)
- Good health and well-being